Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06883305 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
A Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 990
- Enrollment target
- 20
- Study locations
NCT06883305: Recruiting Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca.
NCT06883305 is a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD) that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 990 participants, above the 624-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (59% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06883305, a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 990 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Primary Outcome
The annualised moderate or severe COPD exacerbation rate (based on exacerbations reported by the investigator) up to 76 weeks treatment period compared to placebo.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Tezepelumab
Study Locations (20)
Florida
- Research Site - Clearwater
- Research Site - Cutler Bay
- Research Site - Cutler Bay
- Research Site - DeBary
- Research Site - Gainesville
- Research Site - Homestead
- Research Site - Miami
- Research Site - Miami
- Research Site - Miami
- Research Site - Miami
- Research Site - Orlando
Alabama
- Research Site - Foley
- Research Site - Mobile
- Research Site - Sheffield
Arizona
- Research Site - Phoenix
- Research Site - Phoenix
- Research Site - Tucson
California
- Research Site - Garden Grove
- Research Site - Newport Beach
- Research Site - Torrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 990 participants |
| Start Date | 2025-03-18 |
| Est. Completion | 2029-06-05 |
| Phase | Phase 3 |
What NCT06883305 shows while recruiting
NCT06883305 is an interventional study that assigns participants to a tested intervention. The registered 990 participants enrollment target is mid-sized for trials with a published cap, above the 624-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (59% higher).
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06883305 names 20 study sites across 4 states, led by Florida, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT06883305 about?
NCT06883305 is a clinical study titled "A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)". A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
What is the current status of trial NCT06883305?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 990 participants. The study started on 2025-03-18. Estimated completion is 2029-06-05.
What conditions does trial NCT06883305 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).
What interventions are being tested in trial NCT06883305?
The interventions under investigation include: Placebo (OTHER), Tezepelumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06883305?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06883305 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease (COPD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06883305's enrollment target sits among peer trials
990 14th of 36 higher than 22 of 36 other Chronic Obstructive Pulmonary Disease (COPD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease (COPD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Multi-Center Clean Air Randomized Controlled Trial in COPD
RECRUITING · Phase 3
-
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
RECRUITING · Phase 3
-
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05441709 · 990 participants · NA
Furthering Equity Through Infant Feeding EDucation and Support
- NCT06340646 · 990 participants · NA
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
- NCT07018700 · 990 participants · Phase 3
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
- NCT07221357 · 990 participants · Phase 2
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI